UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 3, 2020
ANTARES PHARMA, INC.
(Exact name of registrant specified in its charter)
Delaware | | 1-32302 | | 41-1350192 |
(State or Other Jurisdiction of Incorporation) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
| | | | |
100 Princeton South, Suite 300, Ewing, NJ | | 08628 |
(Address of Principal Executive Offices) | | (Zip Code) |
(609) 359-3020
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
Common Stock, par value $0.01 per share | | ATRS | | NASDAQ |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On April 3, 2020, James P. Tursi, M.D., tendered his resignation as Executive Vice President, Pharmaceutical Research and Development, Chief Medical Officer of Antares Pharma, Inc. (the “Company”), effective April 17, 2020. Dr. Tursi informed the Company that he has accepted a position at another company. Jonathan S. Jaffe, M.D., the Company’s Vice President, Clinical Development and Medical Affairs, will assume the responsibilities of Dr. Tursi on an interim basis and work with Dr. Tursi to ensure a smooth transition.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | ANTARES PHARMA, INC. |
| | | | |
Date: | | April 9, 2020 | | By: | | /s/ Peter J. Graham |
| | | | Name: | | Peter J. Graham |
| | | | Title: | | Executive Vice President, General Counsel |
